ACAD
Price
$21.58
Change
+$0.56 (+2.66%)
Updated
Jul 9, 04:59 PM (EDT)
Capitalization
3.52B
21 days until earnings call
INTS
Price
$0.31
Change
+$0.02 (+6.90%)
Updated
Jul 9, 04:59 PM (EDT)
Capitalization
7.57M
40 days until earnings call
Interact to see
Advertisement

ACAD vs INTS

Header iconACAD vs INTS Comparison
Open Charts ACAD vs INTSBanner chart's image
ACADIA Pharmaceuticals
Price$21.58
Change+$0.56 (+2.66%)
Volume$36.83K
Capitalization3.52B
Intensity Therapeutics
Price$0.31
Change+$0.02 (+6.90%)
Volume$21.4K
Capitalization7.57M
ACAD vs INTS Comparison Chart in %
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. INTS commentary
Jul 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Hold and INTS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 09, 2025
Stock price -- (ACAD: $21.02 vs. INTS: $0.29)
Brand notoriety: ACAD and INTS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 85% vs. INTS: 199%
Market capitalization -- ACAD: $3.52B vs. INTS: $7.57M
ACAD [@Biotechnology] is valued at $3.52B. INTS’s [@Biotechnology] market capitalization is $7.57M. The market cap for tickers in the [@Biotechnology] industry ranges from $309.49B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileINTS’s FA Score has 0 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • INTS’s FA Score: 0 green, 5 red.
According to our system of comparison, ACAD is a better buy in the long-term than INTS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 2 TA indicator(s) are bullish while INTS’s TA Score has 2 bullish TA indicator(s).

  • ACAD’s TA Score: 2 bullish, 6 bearish.
  • INTS’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, INTS is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а -1.59% price change this week, while INTS (@Biotechnology) price change was -5.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +12.91%. For the same industry, the average monthly price growth was +17.27%, and the average quarterly price growth was +18.94%.

Reported Earning Dates

ACAD is expected to report earnings on Nov 11, 2025.

INTS is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+12.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($3.52B) has a higher market cap than INTS($7.57M). ACAD YTD gains are higher at: 14.550 vs. INTS (-83.511). ACAD has higher annual earnings (EBITDA): 102M vs. INTS (-14.92M). ACAD has more cash in the bank: 682M vs. INTS (929K). INTS has less debt than ACAD: INTS (131K) vs ACAD (56M). ACAD has higher revenues than INTS: ACAD (996M) vs INTS (0).
ACADINTSACAD / INTS
Capitalization3.52B7.57M46,491%
EBITDA102M-14.92M-684%
Gain YTD14.550-83.511-17%
P/E Ratio15.34N/A-
Revenue996M0-
Total Cash682M929K73,412%
Total Debt56M131K42,748%
FUNDAMENTALS RATINGS
ACAD: Fundamental Ratings
ACAD
OUTLOOK RATING
1..100
53
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
26
PRICE GROWTH RATING
1..100
44
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACADINTS
RSI
ODDS (%)
Bearish Trend 2 days ago
60%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
52%
Momentum
ODDS (%)
Bearish Trend 2 days ago
66%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
67%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 22 days ago
73%
Bullish Trend 13 days ago
67%
Declines
ODDS (%)
Bearish Trend 3 days ago
71%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 7 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ZBRA323.065.95
+1.88%
Zebra Technologies Corp
GMRE7.170.05
+0.70%
Global Medical REIT
EFOI2.340.01
+0.57%
Energy Focus
PINC21.92-0.08
-0.36%
Premier
CAAS4.08-0.06
-1.45%
China Automotive Systems

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with AURA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then AURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
+0.67%
AURA - ACAD
44%
Loosely correlated
+1.46%
CRSP - ACAD
43%
Loosely correlated
+7.09%
STTK - ACAD
39%
Loosely correlated
+4.84%
TECH - ACAD
39%
Loosely correlated
+2.22%
PGEN - ACAD
39%
Loosely correlated
+6.92%
More

INTS and

Correlation & Price change

A.I.dvisor tells us that INTS and ACAD have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INTS and ACAD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INTS
1D Price
Change %
INTS100%
+2.40%
ACAD - INTS
28%
Poorly correlated
+0.67%
CCCC - INTS
27%
Poorly correlated
+12.50%
OABI - INTS
25%
Poorly correlated
+10.70%
GPCR - INTS
25%
Poorly correlated
+0.03%
CLGN - INTS
24%
Poorly correlated
+3.70%
More